Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

This study is evaluating the safety and effectiveness of TareSphere, a type of liver-targeted radiation therapy (radioembolization using tiny radioactive beads), in patients with liver cancer (hepatocellular carcinoma) in China. **You may be eligible if...** - You have been diagnosed with hepatocellular carcinoma (liver cancer) - Surgery, ablation, or liver transplant is not suitable for you or you have refused it - Your liver function is relatively preserved (Child-Pugh score of 7 or less) - Your overall physical condition is good to moderate (ECOG score of 0 or 1) - Your key organ functions (blood, liver, kidneys) meet required levels **You may NOT be eligible if...** - Imaging suggests cancer has spread outside the liver (including to lymph nodes) - You have already received treatment for your liver cancer - You have had prior external radiation or internal liver radiation therapy Talk to your doctor to see if this trial is right for you.